Basic Study
Copyright ©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Surg. Jan 27, 2025; 17(1): 97148
Published online Jan 27, 2025. doi: 10.4240/wjgs.v17.i1.97148
Synergistic inhibition of colorectal cancer progression by silencing Aurora A and the targeting protein for Xklp2
Gui-Xian Sheng, Yu-Jia Zhang, Tao Shang
Gui-Xian Sheng, Department of Colorectal Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310000, Zhejiang Province, China
Yu-Jia Zhang, School of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou 310053, Zhejiang Province, China
Tao Shang, Department of Colorectal Surgery, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Traditional Chinese Medicine), Hangzhou 310006, Zhejiang Province, China
Co-corresponding authors: Yu-Jia Zhang and Tao Shang.
Author contributions: Sheng GX, Zhang YJ, and Shang T designed the study; Sheng GX and Shang T performed the research; Zhang YJ analyzed the data and wrote the manuscript; Shang T prepared all figures and provided guidance; All authors have reviewed and approved the final manuscript; Tao Shang and Yu-Jia Zhang contributed equally to this work and should be considered co-correspondence authors.
Institutional review board statement: The study was reviewed and approved by Ethics Committee of the First Affiliated Hospital of Zhejiang Chinese Medical University, No. 2021-K-220-01.
Institutional animal care and use committee statement: This study did not involve any animal experiments.
Conflict-of-interest statement: The authors declare that they have no conflict of interest.
Data sharing statement: Data supporting the findings of this study are available upon request from the corresponding authors.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Tao Shang, Department of Colorectal Surgery, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Traditional Chinese Medicine), No. 54 Youdian Road, Shangcheng District, Hangzhou 310006, Zhejiang Province, China. shangtaomail@163.com
Received: May 24, 2024
Revised: October 10, 2024
Accepted: November 22, 2024
Published online: January 27, 2025
Processing time: 217 Days and 11.4 Hours
Core Tip

Core Tip: In this study, we evaluated three gene datasets and identified 13 crucial genes. Results from SW480 and LOVO cells showed that Aurora kinase A (AURKA) and the targeting protein for Xklp2 (TPX2) blocked cell cycle progression and promoted cell apoptosis of colorectal cancer (CRC). Knockdown of either AURKA, TPX2, or both reduced the invasion and migration ability of CRC cells while inhibiting epithelial-mesenchymal transition. Co-knockdown of AURKA and TPX2 enhanced the inhibition of CRC cells. Combined knockdown was more effective in suppressing the malignant phenotype in CRC, providing ideas and basic data for CRC treatment.